Skip to main content
OpenTrials
Completed

NCT Number: NCT02603315

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malignant Pleural Mesotheliomas Adenoma Lung Diseases Lung Neoplasms Mesothelioma Mesothelioma, Malignant Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Neoplasms, Mesothelial Pleural Neoplasms Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

39 year–84 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams University Hospital

Cairo, Egypt

About this study

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histopathological confirmation of malignant pleural mesothelioma .
  • Full clinical data.
  • Availability for follow up: Personal communication will be attempted in order to collect missing information.

3-The files of all patients will be reviewed to analyze the following :

  • Operative data if done .
  • Pathological review and immunohistochemistry.
  • Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)
  • Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\\S and MRI ).
  • Treatment protocols applied: Radiotherapy and Chemotherapy.
  • Response and survival after treatment .

Exclusion criteria

  • cases not receive chemotherapy ,on available of evaluation after treatment

Treatment and study plan

marker CD74 and vascular endothelial growth factor VEGF

Other

correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment

Primary outcomes

  1. to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival

    Time frame: 3-4 months

    The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

Secondary outcomes

  1. assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74

    Time frame: 3-4 months

    The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Official study title

To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )

Acronym: VITMPM

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Nov 11, 2015
Registry last updated
Jun 1, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.